ADMA
Price
$15.96
Change
+$0.26 (+1.66%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
3.8B
119 days until earnings call
Intraday BUY SELL Signals
CPRX
Price
$22.50
Change
-$0.16 (-0.71%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
2.77B
118 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADMA vs CPRX

Header iconADMA vs CPRX Comparison
Open Charts ADMA vs CPRXBanner chart's image
ADMA Biologics
Price$15.96
Change+$0.26 (+1.66%)
Volume$83.63K
Capitalization3.8B
Catalyst Pharmaceuticals
Price$22.50
Change-$0.16 (-0.71%)
Volume$16.56K
Capitalization2.77B
ADMA vs CPRX Comparison Chart in %
ADMA
Daily Signal:
Gain/Loss:
CPRX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ADMA vs. CPRX commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Hold and CPRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ADMA: $15.69 vs. CPRX: $22.50)
Brand notoriety: ADMA and CPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 50% vs. CPRX: 72%
Market capitalization -- ADMA: $3.8B vs. CPRX: $2.77B
ADMA [@Biotechnology] is valued at $3.8B. CPRX’s [@Biotechnology] market capitalization is $2.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 1 FA rating(s) are green whileCPRX’s FA Score has 1 green FA rating(s).

  • ADMA’s FA Score: 1 green, 4 red.
  • CPRX’s FA Score: 1 green, 4 red.
According to our system of comparison, CPRX is a better buy in the long-term than ADMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 6 TA indicator(s) are bullish while CPRX’s TA Score has 4 bullish TA indicator(s).

  • ADMA’s TA Score: 6 bullish, 3 bearish.
  • CPRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ADMA is a better buy in the short-term than CPRX.

Price Growth

ADMA (@Biotechnology) experienced а -2.12% price change this week, while CPRX (@Biotechnology) price change was -1.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

ADMA is expected to report earnings on Mar 19, 2026.

CPRX is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADMA($3.8B) has a higher market cap than CPRX($2.77B). ADMA has higher P/E ratio than CPRX: ADMA (18.55) vs CPRX (13.16). CPRX YTD gains are higher at: 7.810 vs. ADMA (-6.968). CPRX has higher annual earnings (EBITDA): 281M vs. ADMA (163M). CPRX has more cash in the bank: 653M vs. ADMA (90.3M). CPRX has less debt than ADMA: CPRX (2.99M) vs ADMA (83.8M). CPRX has higher revenues than ADMA: CPRX (558M) vs ADMA (474M).
ADMACPRXADMA / CPRX
Capitalization3.8B2.77B137%
EBITDA163M281M58%
Gain YTD-6.9687.810-89%
P/E Ratio18.5513.16141%
Revenue474M558M85%
Total Cash90.3M653M14%
Total Debt83.8M2.99M2,802%
FUNDAMENTALS RATINGS
ADMA vs CPRX: Fundamental Ratings
ADMA
CPRX
OUTLOOK RATING
1..100
1320
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
3621
SMR RATING
1..100
1634
PRICE GROWTH RATING
1..100
6248
P/E GROWTH RATING
1..100
9973
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPRX's Valuation (61) in the Pharmaceuticals Other industry is in the same range as ADMA (69) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

CPRX's Profit vs Risk Rating (21) in the Pharmaceuticals Other industry is in the same range as ADMA (36) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

ADMA's SMR Rating (16) in the Biotechnology industry is in the same range as CPRX (34) in the Pharmaceuticals Other industry. This means that ADMA’s stock grew similarly to CPRX’s over the last 12 months.

CPRX's Price Growth Rating (48) in the Pharmaceuticals Other industry is in the same range as ADMA (62) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

CPRX's P/E Growth Rating (73) in the Pharmaceuticals Other industry is in the same range as ADMA (99) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMACPRX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 8 days ago
86%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 21 days ago
67%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signal:
Gain/Loss:
CPRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VHIAX42.850.29
+0.68%
JPMorgan Growth Advantage A
PLVIX20.21N/A
N/A
Principal Large Cap Value III Inst
ISMOX3.61N/A
N/A
Voya MidCap Opportunities Port S
FCVFX32.91N/A
N/A
Fidelity Advisor Value C
SFREX9.91N/A
N/A
Schwab Fundamental Global Real Estt Idx

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with CPRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then CPRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
+1.69%
CPRX - ADMA
41%
Loosely correlated
-0.71%
OCUL - ADMA
41%
Loosely correlated
+2.81%
XENE - ADMA
40%
Loosely correlated
+0.15%
CLDX - ADMA
39%
Loosely correlated
-2.58%
VIR - ADMA
39%
Loosely correlated
-1.18%
More